Abstract| Volume 18, ISSUE 6, SUPPLEMENT , S21-S22, June 2016

Intravenous Administration of Allogeneic Mesenchymal Stem Cells in Patients with Cerebellar Ataxias: A Phase I/IIa Clinical Trial

      Introduction: Mesenchymal stem cells (MSCs) are immune evasive and can be transplanted to HLA-unmatched allogeneic recipients. Animal studies indicated that transplantation of MSCs improved the motor function in SCA 2 transgenic mice. This is a phase I/II clinical trial aiming to evaluate the safety and efficacy of allogeneic mesenchymal stem cells (MSCs) for the treatment of cerebellar ataxia.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect